Project Grant R01CA308586
Award Date 8/13/26
Completion Date 7/31/31
Dollars Obligated $367K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
- The National Cancer Institute awarded The Ohio State University $511,944 on July 16, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate dual targeting of oncogenic signaling and immune suppression in high-risk T-cell acute lymphoblastic leukemia. The research examines a novel signaling pathway involving ATAD2, regulated by the CK2/IKAROS axis, which drives T-ALL cell cycle progression. Preliminary data show that dual targeting of ATAD2 signaling and the CK2/IKAROS...
- The National Cancer Institute awarded The Ohio State University $373,926 under the Cancer Biology Research program (CFDA 93.396) on July 1, 2026, to develop and optimize dual-labeling proteomics methodology for studying chromatin assembly and epigenetic inheritance at DNA replication forks. The project combines threonine-derived non-canonical amino acid tagging (THRONCAT) with isolation of proteins on nascent DNA (IPOND) to selectively enrich and analyze newly synthesized histones while...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Ohio State University a $449,222 Project Grant effective August 20, 2025, through July 31, 2030, under the Cancer Treatment Research program (CFDA 93.395). This award funds research to elucidate the cellular and molecular mechanisms by which PD-1H (Programmed Death-1 Homolog, also known as VISTA) mediates immune suppression in acute myeloid leukemia (AML) and to evaluate its potential as a therapeutic target. The...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $394,695 to The Ohio State University on June 17, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate computational approaches for detecting and characterizing infiltrating immune cells in breast cancer. The recipient will develop computational methods to enumerate and phenotype tumor-infiltrating lymphocytes (TILs) and...
- The National Cancer Institute, within the Department of Health and Human Services National Institutes of Health, awarded $831,988 to Trustees of Tufts College (doing business as Tufts University School of Medicine) on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396). The award funds a five-year project investigating the role of ASAH1-driven ceramide metabolism in Epstein Barr Virus-driven B-cell transformation under germinal center hypoxia. The research addresses...
- The National Cancer Institute awarded a $695,155 Cooperative Agreement to Fred Hutchinson Cancer Center on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to optimize post-transplantation cyclophosphamide (PTCY) dosing for hematopoietic cell transplantation with peripheral blood stem cell grafts. The award funds a phase I/II clinical trial examining PTCY dose de-escalation in recipients of HLA-matched or HLA-haploidentical donor transplants using reduced-intensity...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $1,574,578 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel targeted modified mRNA delivery strategies for donation after circulatory death (DCD) heart transplantation. The research addresses primary graft dysfunction (PGD), an ischemia-reperfusion injury occurring in approximately 35 percent of heart transplants and driven by hyper-inflammatory responses involving...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $394,214 to the University of North Carolina at Chapel Hill on May 19, 2026, under the Cancer Biology Research program (CFDA 93.396). The award funds development of a transgenic mouse model and novel cell culture reagents for Epstein-Barr virus-driven solid tumors, including nasopharyngeal carcinoma and gastric cancer. The proposed transgenic mice will be fully...
- The National Cancer Institute awarded Yale University $677,621 on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and validate a blood test for early detection of non-Hodgkin's lymphoma in people with HIV. The research measures altered methylation patterns of tumor-derived cell-free DNA fragments in blood as biomarkers of lymphomagenesis, specifically evaluating hypermethylation of Epstein-Barr virus DNA and gene promoters in infected B cell genomes that arise...
- The National Cancer Institute awarded the Research Institute At Nationwide Children's Hospital $639,295 on May 8, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate the molecular mechanisms of altered DNA binding and chromatin regulation by FET::ETS oncogenes. The project, which runs through April 30, 2031, focuses on understanding how fusion oncoproteins—specifically EWSR1::FLI1, the oncogenic driver of Ewing sarcoma—acquire neomorphic functions through...